Unique ID issued by UMIN | UMIN000005381 |
---|---|
Receipt number | R000006386 |
Scientific Title | Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis |
Date of disclosure of the study information | 2011/04/07 |
Last modified on | 2012/04/06 08:09:53 |
Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis
Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis
Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis
Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis
Japan |
colorectal cancer with liver metastasis
Gastrointestinal surgery |
Malignancy
NO
The primary objective of this study was efficasy of FOLFOXIRI+anti-EGFR monoclonal antibody for liver metastasis of colorectal cancer
Safety
Exploratory
Pragmatic
Phase II
R0 rejective rate
Safety
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
day1:CPT-11(150mg/m2),L-OHP(65mg/m2),L-LV(200mg/m2)
day1-2:5-FU(3200mg/m2)48hr civ,
day1:Panitumumab(6mg/kg)
or day1 and 7 cetuximab(400mg/m2)
ever 2 weeks
20 | years-old | <= |
Not applicable |
Male and Female
1)histlogically colorectal adenocarcinoma and KRAS mutation status was wildtype
2)without primary surgery chemotherapy radiotherapy
3)within liver metastasis
4)a)age 20-
b)PS(ECOG)0-1
c)without interstitinal lung fibrosis
d)adequate organ function,14 days before entry
hemoglobin:>9.0g/dl
leukocyte count:>3000-12000/mm3
neutrophl cell count:>1500/mm3
serum bilirubin level <1.5mg/dl
AST,ALT:<200U/I
serum creatinine level:<1.2mg/dl
estimate creatinine clearance level:>60ml/min
nomal ECG within 28days before entry
5)written informed consent from patients
1)had a previous serious medical illness or allergy for drugs
2)had active double cancer
3)had a hypersensitivity or taboo for test drugs
4)had active infection disease(oner 38.0C fever)
5)had serious complication(ireus,renal function,liver function,heart failure,diabetes within could not control)
6)had serious bowel blockage
7)had serious interstitinal fibrosis
8)had pleural effusion or abdominal dropsy within could not control
9)had watersolubility diarrhea
10)had brain metastasis
11)pregnant or lactating woman,woman who are capable of pregnancy or intend to get pregnant,man who are not inend to contraception
12)had mental illness
13)expect referred to above physician in charge of this trial gave a diagnosis the patient who can not join this trial for the safety
20
1st name | |
Middle name | |
Last name | Mitsuo Shimada |
Tokushima university
Department of surgery and transplantation
3-18-15 Kuramoto,Tokushima
1st name | |
Middle name | |
Last name |
Tokushima university
Department of surgery and transplantation
Tokushima university
Department of surgery and transplantation
Tokushima university
Self funding
NO
2011 | Year | 04 | Month | 07 | Day |
Unpublished
Preinitiation
2011 | Year | 04 | Month | 05 | Day |
2011 | Year | 05 | Month | 01 | Day |
2014 | Year | 03 | Month | 01 | Day |
2011 | Year | 04 | Month | 05 | Day |
2012 | Year | 04 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006386
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |